Short Term or BTST Bumper Call
Buy Umang Dairy at CMP of 80.3 - 81 and dips till 78
Sl 75
Targets:- 84 - 85 - 86.5 - 88 - 89 - 90 - 92+
Above 92 we can see 95 - 99 - 105+
Disclaimer:- I am not SEBI Registered. Please consult your financial advisor before investing.
Buy Umang Dairy at CMP of 80.3 - 81 and dips till 78
Sl 75
Targets:- 84 - 85 - 86.5 - 88 - 89 - 90 - 92+
Above 92 we can see 95 - 99 - 105+
Disclaimer:- I am not SEBI Registered. Please consult your financial advisor before investing.
Market Wizard
Short Term Bumper Fundamental Call Buy Bajaj Steel (BSE - 507944) at cmp of 592 - 596 and dips till 570 Sl 555 Short Term Targets:- 600 - 603 - 606 - 610 - 614 - 618 - 625+ Above 625 we can see 645 - 660+ Disclaimer:- I am not SEBI Registered. Please consult…
BAJAJ STEEL 1314.75❤️❤️❤️
UC LOCKED
UC LOCKED
Brightcom Group Investors Group
This group is only for discussing and updating on all developments in BCG (Brightcom Group) so we request all the members of this group to strictly limit their discussions to BCG and don't share information without any authenticity.
https://t.me/brightcomgroup
This group is only for discussing and updating on all developments in BCG (Brightcom Group) so we request all the members of this group to strictly limit their discussions to BCG and don't share information without any authenticity.
https://t.me/brightcomgroup
NIIT: CO AND AXIS BANK PARTNER TO LAUNCH A DIGITAL BANKING ACADEMY || PROGRAMME DESIGNED TO BUILD FUTURE READY FINTECH PROFESSIONALS FOR AXIS BANK
MR. CHETAN KEDIA: SEAMEC: NOMURA SINGAPORE LIMITED ODI BOUGHT 2.34% STAKE IN CO DURING Q1
MR. CHETAN KEDIA: TATA MOTORS: S&P REVISES JLR AUTO OUTLOOK TO STABLE ON `STRONG COST CONTROL
MR. CHETAN KEDIA: TATA MOTORS: S&P REVISES JLR AUTO OUTLOOK TO STABLE ON `STRONG COST CONTROL
KOPRAN: CO RESEARCH LABORATORIES LTD., A WHOLLY OWNED SUBSIDIARY HAS UNDERTAKEN EXPANSION AND UPGRADATION OF VARIOUS PLANTS AT ITS ACTIVE PHARMACEUTICAL INGREDIENTS FACILITY AT MAHAD II THE EXPANSIONS OF TWO PLANTS WERE COMPLETED BY APRIL 2021 END AND RESUMED OPERATIONS II THE EXPANSION AND UPGRADATION OF THE STERILE PLANT WAS COMPLETED AND OPERATIONS RESUMED BY JUNE 2021 END
*Shyam Metalics And Energy Ltd.* | *CMP* Rs. 415 | *M Cap* Rs. 10587 Cr | *52 W H/L* 415/361
(Nirmal Bang Retail Research)
*March Quarter Result*
*Result improved*
Revenue from Operations came at Rs. 2350.5 Cr (38.3% QoQ, 116.9% YoY) vs QoQ Rs. 1699.6 Cr, YoY Rs. 1083.7 Cr
EBIDTA came at Rs. 626.8 Cr (76.8% QoQ, 230.3% YoY) vs QoQ Rs. 354.5 Cr, YoY Rs. 189.7 Cr
EBITDA Margin came at 26.7% vs QoQ 20.9%, YoY 17.5%
Adj. PAT came at Rs. 387.5 Cr vs QoQ Rs. 215.8 Cr, YoY Rs. 79.7 Cr
Quarter EPS is Rs. 15.2
Share is trading at EV/EBITDA of 7.8x FY21 EBITDA.
(Nirmal Bang Retail Research)
*March Quarter Result*
*Result improved*
Revenue from Operations came at Rs. 2350.5 Cr (38.3% QoQ, 116.9% YoY) vs QoQ Rs. 1699.6 Cr, YoY Rs. 1083.7 Cr
EBIDTA came at Rs. 626.8 Cr (76.8% QoQ, 230.3% YoY) vs QoQ Rs. 354.5 Cr, YoY Rs. 189.7 Cr
EBITDA Margin came at 26.7% vs QoQ 20.9%, YoY 17.5%
Adj. PAT came at Rs. 387.5 Cr vs QoQ Rs. 215.8 Cr, YoY Rs. 79.7 Cr
Quarter EPS is Rs. 15.2
Share is trading at EV/EBITDA of 7.8x FY21 EBITDA.
_*Closing Bell...!!!*_
_Banks, RIL Send Sensex 486 Points Lower; Nifty Below 15750; Sail, Tata Motors Tank Up To 4%._
_*Nifty*_- 15728 (-152)
_*Sensex*_- 52569 (-486)
_*Nifty Bank*_- 35274 (-497)
_*Nifty IT*_- 28749 (+14)
_*Gold*_- 48094 (+184)
_*Silver*_- 69300 (-65)
_*Crude Oil*_- 5346 (-46)
_*Natural Gas*_- 267 (0)
_*$/₹*_- 74.70
_*Top Gainers*_- TASTYBITE, JUSTDIAL, SOBHA, DOLAT
_*Top Losers*_- HINDPETRO, RENUKA, CSBBANK, SAIL
_*Most Active*_- TATAMOTORS, TATASTEEL, JUSTDIAL, RELIANCE
_*Advances*_- 766
_*Declines*_- 1165
_*Unchanged*_- 334
_Banks, RIL Send Sensex 486 Points Lower; Nifty Below 15750; Sail, Tata Motors Tank Up To 4%._
_*Nifty*_- 15728 (-152)
_*Sensex*_- 52569 (-486)
_*Nifty Bank*_- 35274 (-497)
_*Nifty IT*_- 28749 (+14)
_*Gold*_- 48094 (+184)
_*Silver*_- 69300 (-65)
_*Crude Oil*_- 5346 (-46)
_*Natural Gas*_- 267 (0)
_*$/₹*_- 74.70
_*Top Gainers*_- TASTYBITE, JUSTDIAL, SOBHA, DOLAT
_*Top Losers*_- HINDPETRO, RENUKA, CSBBANK, SAIL
_*Most Active*_- TATAMOTORS, TATASTEEL, JUSTDIAL, RELIANCE
_*Advances*_- 766
_*Declines*_- 1165
_*Unchanged*_- 334
🇮🇳*Business News Headlines*🇮🇳
*Economic Times*
Ø JSPL plans over Rs 1 lakh crore investment in Odisha in next 10 years
Ø Lenders discuss option to invite fresh bids for RCom's assets with resolution professional
Ø Tata Steel sees 73% of biz from India over 10 years
Ø Tata Power shareholders approve reappointment of N Chandrasekaran as director
Ø NSE-BSE bulk deals: Texas retirement fund buys stake in H.G. Infra
Ø Chip shortage to affect Tata Motors' near-term profitability
Ø Piramal Capital to raise up to Rs 1,000 crore via NCDs
Ø Reliance Infra gets shareholders nod to raise up to Rs 551 cr via preferential allotment
Ø Sebi seeks info on trades by execs of big cos where promoters hiked stake
Ø DHFL resolution: NCLAT issues notices to lenders, Piramal on 63 Moons Tech's plea
Ø Tycoon Gautam Adani seeks $1 billion to refinance Mumbai airport debt
*Business Standard*
Ø PNB advises Housing arm to rejig Carlyle deal as per Sebi order
Ø Matrimony.com to buy wedding planning firm ShaadiSaga for Rs 11 cr
Ø JSPL announces over Rs 1 trillion investment in Odisha in next 10 years
Ø Private banks' loan books shrink in Q1 amid second wave of Covid-19
Ø NCLAT issues notices to lenders, Piramal on 63 Moons Technologies' plea
Ø PNB advises Housing arm to rejig Carlyle deal as per Sebi order
Ø Edtech firm upGrad earmarks $250 mn for M&A, non-linear growth
Ø Vedanta's funding ops to improve on raising debt cap at subsidiary: S&P
Ø Bajaj Finance books fewer new loans in June quarter over March
Ø Govt's move to bring DPE under FinMin to aid privatisation process
*Financial Express*
Ø Fitch cuts India growth forecast to 10 pc, says rapid vaccination to support revival
Ø Cabinet Reshuffle 2021: From Health Minister Harsh Vardhan to MoS Babul Supriyo, 12 union ministers lose cabinet berths
Ø Info Edge reduces OFS size in Zomato IPO by half
Ø Increasing imports of tea a matter of great concern
Ø Sebi levies nearly Rs 23 lakh fine on 16 entities
Ø Some states to roll out labour reforms in 3-5 months
Ø Indian IT industry to post strong recovery with 11% revenue growth in FY22: Crisil
Ø Sebi cuts time period for filing application to obtain NOC for release of 1 pc of issue amount
Ø CapitaLand launches Rs 2,250 cr fund to develop logistics parks in India
Ø RBI notifies inclusion of retail, wholesale trade under MSME category
*Mint*
Ø PNB tells housing arm to propose fresh plan, reconsider ₹4,000 cr Carlyle deal
Ø Coal shows its staying power as economies bounce back
Ø Cabinet reshuffle: PM Modi meets BJP MPs ahead of rejig
Ø Paytm reshuffles board before floating mega IPO
Ø JK Tyre collaborates with Hyundai Motor for its new vehicle Alcazar
Ø Investment advisors cannot take power of attorney from clients: Sebi
Ø Indian banks to see bad loans peaking post FY23: Fitch
Ø Tata Power sets up fast EV charging station at Statue of Unity, Gujarat
Ø Clean Science and Technology's favourable financials reflect in IPO valuations
Ø ‘India will contribute to being an engine of growth for global economy’
Ø India's domestic traffic was 71% lower in May 2021 compared to May 2019: IATA
*Economic Times*
Ø JSPL plans over Rs 1 lakh crore investment in Odisha in next 10 years
Ø Lenders discuss option to invite fresh bids for RCom's assets with resolution professional
Ø Tata Steel sees 73% of biz from India over 10 years
Ø Tata Power shareholders approve reappointment of N Chandrasekaran as director
Ø NSE-BSE bulk deals: Texas retirement fund buys stake in H.G. Infra
Ø Chip shortage to affect Tata Motors' near-term profitability
Ø Piramal Capital to raise up to Rs 1,000 crore via NCDs
Ø Reliance Infra gets shareholders nod to raise up to Rs 551 cr via preferential allotment
Ø Sebi seeks info on trades by execs of big cos where promoters hiked stake
Ø DHFL resolution: NCLAT issues notices to lenders, Piramal on 63 Moons Tech's plea
Ø Tycoon Gautam Adani seeks $1 billion to refinance Mumbai airport debt
*Business Standard*
Ø PNB advises Housing arm to rejig Carlyle deal as per Sebi order
Ø Matrimony.com to buy wedding planning firm ShaadiSaga for Rs 11 cr
Ø JSPL announces over Rs 1 trillion investment in Odisha in next 10 years
Ø Private banks' loan books shrink in Q1 amid second wave of Covid-19
Ø NCLAT issues notices to lenders, Piramal on 63 Moons Technologies' plea
Ø PNB advises Housing arm to rejig Carlyle deal as per Sebi order
Ø Edtech firm upGrad earmarks $250 mn for M&A, non-linear growth
Ø Vedanta's funding ops to improve on raising debt cap at subsidiary: S&P
Ø Bajaj Finance books fewer new loans in June quarter over March
Ø Govt's move to bring DPE under FinMin to aid privatisation process
*Financial Express*
Ø Fitch cuts India growth forecast to 10 pc, says rapid vaccination to support revival
Ø Cabinet Reshuffle 2021: From Health Minister Harsh Vardhan to MoS Babul Supriyo, 12 union ministers lose cabinet berths
Ø Info Edge reduces OFS size in Zomato IPO by half
Ø Increasing imports of tea a matter of great concern
Ø Sebi levies nearly Rs 23 lakh fine on 16 entities
Ø Some states to roll out labour reforms in 3-5 months
Ø Indian IT industry to post strong recovery with 11% revenue growth in FY22: Crisil
Ø Sebi cuts time period for filing application to obtain NOC for release of 1 pc of issue amount
Ø CapitaLand launches Rs 2,250 cr fund to develop logistics parks in India
Ø RBI notifies inclusion of retail, wholesale trade under MSME category
*Mint*
Ø PNB tells housing arm to propose fresh plan, reconsider ₹4,000 cr Carlyle deal
Ø Coal shows its staying power as economies bounce back
Ø Cabinet reshuffle: PM Modi meets BJP MPs ahead of rejig
Ø Paytm reshuffles board before floating mega IPO
Ø JK Tyre collaborates with Hyundai Motor for its new vehicle Alcazar
Ø Investment advisors cannot take power of attorney from clients: Sebi
Ø Indian banks to see bad loans peaking post FY23: Fitch
Ø Tata Power sets up fast EV charging station at Statue of Unity, Gujarat
Ø Clean Science and Technology's favourable financials reflect in IPO valuations
Ø ‘India will contribute to being an engine of growth for global economy’
Ø India's domestic traffic was 71% lower in May 2021 compared to May 2019: IATA
*Pharmaceuticals*
*Strong Growth momentum to sustain*
*Q1FY2022 Results Preview*
*Sector: Pharmaceuticals*
*Sector View: Positive*
Pharmaceutical companies in Sharekhan’s universe are expected to report strong performance for Q1FY2022 on a y-o-y basis, driven by a sturdy performance of the domestic business. The performance of the companies is expected to be reflective of the strong growth in the Indian Pharmaceutical Markets (IPM) in Q1FY22 largely attributable to a low base in the corresponding quarter of the previous year coupled with a revival in acute therapies – anti-infective, pain / analgesics amongst others. Also the VMN (Vitamins/ Minerals/ Nutrients) space grew in strong double digits.
*Outlook*
*Growth levers intact:* Indian pharmaceutical companies are better placed to harness opportunities and post healthy growth going ahead. Indian companies are among the most competitive globally and hold a sizeable market share in most developed as well as other markets. Indian pharmaceutical companies have developed strong capabilities over the years, which are depicted in their inherent strength.
*Valuation*
*Sector view - Positive:* The pharma index had largely underperformed the benchmark indices, considering a longer tenure from around April 2015 till date. However, in a little over a year, the Nifty Pharma index had bucked its trend and outperformed the benchmark, reporting a sturdy 76% return as compared to ~32% return by the benchmark. Strong outperformance is expected to continue going ahead as well and we see this as the beginning of a multi-year bull run for pharmaceutical companies.
*Key Risks* 1) Adverse regulatory changes / delay in approvals could impact the sector’s performance. 2) Currency volatility could dent earnings.
*Leaders:* Laurus Labs, Sun Pharmaceutical Industries, Solara Active Pharma Science
*Laggards:* Shilpa Medicare, IPCA Laboratories
*Preferred Picks* Large Caps: Aurobindo, Cadila, Lupin, Dr Reddy’s, Sun Pharma, Biocon
Mid Caps: Gland Pharma, Laurus Labs, Strides Pharma Sciences, Solara Active Pharma Science, Abbott India, Caplin Point Laboratories
*Strong Growth momentum to sustain*
*Q1FY2022 Results Preview*
*Sector: Pharmaceuticals*
*Sector View: Positive*
Pharmaceutical companies in Sharekhan’s universe are expected to report strong performance for Q1FY2022 on a y-o-y basis, driven by a sturdy performance of the domestic business. The performance of the companies is expected to be reflective of the strong growth in the Indian Pharmaceutical Markets (IPM) in Q1FY22 largely attributable to a low base in the corresponding quarter of the previous year coupled with a revival in acute therapies – anti-infective, pain / analgesics amongst others. Also the VMN (Vitamins/ Minerals/ Nutrients) space grew in strong double digits.
*Outlook*
*Growth levers intact:* Indian pharmaceutical companies are better placed to harness opportunities and post healthy growth going ahead. Indian companies are among the most competitive globally and hold a sizeable market share in most developed as well as other markets. Indian pharmaceutical companies have developed strong capabilities over the years, which are depicted in their inherent strength.
*Valuation*
*Sector view - Positive:* The pharma index had largely underperformed the benchmark indices, considering a longer tenure from around April 2015 till date. However, in a little over a year, the Nifty Pharma index had bucked its trend and outperformed the benchmark, reporting a sturdy 76% return as compared to ~32% return by the benchmark. Strong outperformance is expected to continue going ahead as well and we see this as the beginning of a multi-year bull run for pharmaceutical companies.
*Key Risks* 1) Adverse regulatory changes / delay in approvals could impact the sector’s performance. 2) Currency volatility could dent earnings.
*Leaders:* Laurus Labs, Sun Pharmaceutical Industries, Solara Active Pharma Science
*Laggards:* Shilpa Medicare, IPCA Laboratories
*Preferred Picks* Large Caps: Aurobindo, Cadila, Lupin, Dr Reddy’s, Sun Pharma, Biocon
Mid Caps: Gland Pharma, Laurus Labs, Strides Pharma Sciences, Solara Active Pharma Science, Abbott India, Caplin Point Laboratories